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Abstract
Background: In resource-limited settings, where resistance testing is unavailable, confirmatory testing for patients
with high viral loads (VL) delays antiretroviral therapy (ART) switches for persons with resistance. We developed a
risk score algorithm to predict need for ART change by identifying resistance among persons with persistently
elevated VL.
Methods: We analyzed data from a Phase IV open-label trial. Using logistic regression, we identified demographic
and clinical characteristics predictive of need for ART change among participants with VLs ≥1000 copies/ml, and
assigned model-derived scores to predictors. We designed three models, including only variables accessible in
resource-limited settings.
Results: Among 290 participants with at least one VL ≥1000 copies/ml, 51 % (148/290) resuppressed and did not
have resistance testing; among those who did not resuppress and had resistance testing, 47 % (67/142) did not
have resistance and 53 % (75/142) had resistance (ART change needed for 25.9 % (75/290)). Need for ART change
was directly associated with higher baseline VL and higher VL at time of elevated measure, and inversely associated
with treatment duration. Other predictors included body mass index and adherence. Area under receiver operating
characteristic curves ranged from 0.794 to 0.817. At a risk score ≥9, sensitivity was 14.7–28.0 % and specificity was
96.7–98.6 %.
Conclusions: Our model performed reasonably well and may be a tool to quickly transition persons in need of ART
change to more effective regimens when resistance testing is unavailable. Use of this algorithm may result in public
health benefits and health system savings through reduced transmissions of resistant virus and costs on laboratory
investigations.
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Background
The World Health Organization (WHO) recommends
viral load (VL) as the preferred method for monitoring
antiretroviral therapy (ART) and diagnosing viral failure
in HIV-infected patients [1]. An elevated VL is an
important gauge of treatment effectiveness, indicating
poor adherence and/or drug resistance [2–5]. Failing to
switch persons with drug resistance to second-line
therapy in a timely manner increases morbidity and
mortality, likelihood of second-line treatment failure,
and transmission of resistant virus [2, 6–15]. Drug resist-
ance testing is rarely available in resource-limited
settings, where the majority of persons accessing ART
reside [16]. Distinguishing persons with modifiable poor
adherence without resistance mutations from persons
with drug resistance (for whom improved adherence will
not result in viral resuppression) is critical to reduce the
spread of resistance and improve effectiveness of
second-line therapies.
Current VL monitoring algorithms require confirmatory
testing for elevated initial tests (Fig. 1) [1]. This two-step
process presents an opportunity for counseling that may
improve adherence leading to virological resuppression
[17]. However, for persons with resistant viruses, requiring
a second test unnecessarily postpones the treatment
switch. The delays introduced with confirmatory testing
are especially relevant in resource-limited settings: pro-
grammatic and patient-related obstacles may substantially
increase the interval between first and confirmatory
testing. Among persons with confirmed virological failure
in South Africa, switch to second-line therapy took
>5 months after confirmatory VL [18, 19].
In sub-Saharan Africa, >25 % of ART persons may not
achieve viral suppression by 12 months [20], and rates of
virological failure may be as high as 14 % at five years
[19]. With nearly ten million persons receiving ART in
low- and middle-income countries [21], eliminating con-
firmatory testing for even a fraction of ART-resistant
persons will produce substantial cost savings. Further-
more, early identification of treatment failure may avoid
significant morbidity and mortality for patients who
otherwise remain on inappropriate therapy.
Fig. 1 World Health Organization viral load testing strategy for treatment failure [1]. Persons eligible for viral load testing may be tested using
plasma-based assays or dried blood spots. For plasma assays, a viral load >1000 copies/ml prompts an evaluation of adherence to antiretroviral
therapy and targeted adherence counseling if deficiencies in adherence are observed. The viral load test is repeated 3 to 6 months later
(confirmatory test). Patient management is dictated by results of this second test – patients with confirmed elevated (>1000 copies/ml) viral loads
are switched to second-line therapy. The dashed arrow represents implementation of the risk score algorithm. Persons with a risk score exceeding
the predefined algorithm threshold would be switched immediately to second-line therapy
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Distinguishing persons with elevated viremia with with-
out drug resistance mutations is challenging in resource-
limited settings where resistance testing is unavailable. A
simple risk score algorithm may help providers identify
patients with probable ART resistance who could be
switched to second-line therapy immediately without con-
firmatory testing. Using patient demographics, clinical,
and laboratory-based predictors that would be readily
available in most clinical settings, we developed a risk
score algorithm to predict the need for ART change by
identifying resistance among patients with persistently
elevated VL. Patients exceeding a pre-specified risk score
threshold could be switched immediately; patients below
this threshold would have confirmatory VL testing prior
to treatment switch decisions.
Methods
Study setting and population
Eligible participants in the Prospective Evaluation of Anti-
retrovirals in Resource-Limited Settings (PEARLS) trial
(Adult AIDS Clinical Trials Group (ACTG) A5175,
NCT00084136) were studied. PEARLS was an open-label,
Phase IV, randomized clinical trial that investigated effi-
cacy and safety of once- vs. twice-daily regimen dosing.
Details of the PEARLS study population and design have
been described elsewhere [22]. In brief, A5175 enrolled
1571 HIV-infected participants ≥18 years old from nine
countries, over-sampling participants from resource-
limited settings. Participants were excluded from PEARLS
if they: had a CD4 cell count >300 cells/mm3, previous ex-
posure to ART (exception for women who received ART
for prevention of mother-to-child transmission), were
pregnant, or were acutely ill and/or clinically unstable.
PEARLS was approved by institutional review boards and
ethics committees at participating institutions.
This study is a post-hoc analysis of a subset of de-
identified data restricted to participants initiated on non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based
regimens (lamivudine/zidovudine/efavirenz or emtricita-
bine/tenofovir/efavirenz) who had at least one VL ≥1000
copies/ml at any point after week 16 of enrollment. This
population was distinct from the A5175 definition of failure
which required two consecutive measurements of plasma
HIV-1 RNA ≥1000copies/ml after 16-weeks or disease
progression. Primary analyses included participants from all
study sites; a sensitivity analysis restricted the population to
participants enrolled from resource-limited settings. This
analysis was approved by the University of North Carolina,
School of Medicine Institutional Review Board.
Data collection
Per A5175 study protocol, participants received a targeted
physical exam, adherence interview, serum chemistries,
CD4 lymphocyte count, and plasma HIV RNA (Roche
Amplicor Monitor assay [v1.5]) at least every eight weeks.
Any treatment modification (participant, provider, or
protocol-mandated) was assessed at each visit.
Diagnosis criteria were collected using a standardized
case report form.
Resistance tests were done retrospectively at four re-
gional laboratories participating in the National Institute
of Allergy and Infectious Diseases Division of AIDS
Virology Quality Assurance program, coordinated by the
HIV Prevention Trials Network Laboratory Center, using
ViroSeq HIV-1 Genotyping Assay (Celera Diagnostics,
Alameda, California) on stored specimens [23]. Resistance
testing was done for participants meeting study-specific
virological failure criteria (defined below) or who had
disease progression (new or recurrent AIDS-defining
opportunistic infection or malignancy) ≥12 weeks after
randomization.
Measures
The outcome (need for ART change after first VL ≥1000
copies/ml) was assessed using the following algorithm:
resuppression (<1000 copies/ml) – no ART change
needed; no resuppression and no resistance – no ART
change needed; and no resuppression and resistance –
ART change needed. Participants with NRTI or NNRTI
resistance mutations, defined by 2014 International
AIDS Society guidelines (excluding mutation 101P),
were classified as resistant [24]. Resistance to protease
inhibitors (PI) were not included; this class of drugs is
reserved for second-line therapy and thus, if observed in
the absence of NRTI/NNRTI resistance, would not be an
indication for treatment change from first-line regimen.
We did not distinguish between baseline and acquired
resistance. Resistance testing was not done on partici-
pants who had a VL ≥1000 copies/ml and resuppressed
at their subsequent study visit. Any participant who
resuppressed was classified as not needing ART change.
Participants who had two sequential study visits with
VL ≥1000 copies/ml, but who did not have a resist-
ance test, were excluded.
Potential predictors of needing ART change included
demographics, clinical diagnoses prior to treatment
initiation, immunological markers (CD4 cell count), self-
reported and provider-assessed ART adherence, and ther-
apy duration (based on the number of days between ART
initiation and a participant’s first VL ≥1000 copies/ml).
Per WHO and other country ART guidelines, the six-
month visit is frequently identified as the first point that a
participant is eligible for VL monitoring [1, 25, 26]. A six-
month visit was defined as any time point ≥16-week visit
and ≤ 212 days after ART initiation; this time frame in-
cludes an acceptable 30-day extension of the six-month
window period. The 12-month visit was similarly classified
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as any time after the six-month window up to and includ-
ing 30 days after 12 months on ART (395 days).
Statistical analyses
All analyses were conducted using Stata statistical software
(Version 13.0; Stata Corporation, College Station, TX).
We constructed three multivariable models to predict
need for ART change that reflected variations in
availability of CD4 and VLs at time of ART initiation.
Although many countries have scaled up access to CD4
testing to determine ART eligibility, the roll-out of
Option B+, in which HIV-infected pregnant women are
initiated on lifelong ART regardless of CD4, could mean
that many persons will not have a CD4 cell count at
treatment initiation [1]. In light of these policies and the
capacity constraints in resource-limited settings, models
were constructed to reflect three scenarios:
 Model 1 assumed that VL and CD4 at ART
initiation were available, so both were included as
eligible predictors.
 Model 2 assumed that treatment initiation CD4 was
available but that treatment initiation VL was not
and thus excluded as an eligible predictor.
 Model 3 assumed that neither treatment initiation
VL nor CD4 were available; thus neither was
included as eligible predictors.
To evaluate the association between predictors and
need for ART change, we calculated unadjusted preva-
lence odds ratios (OR) and 95 % confidence intervals
(CI) for each potential predictor in each model [27].
The full models contained all variables with bivariate
p-values <0.5; this high threshold was chosen to ensure
that available important predictors were considered [28].
Variables with low frequency, extreme collinearity, or
insufficient detail to permit clinical implementation were
excluded, regardless of p-value. We tested four categori-
zations of time on treatment and selected the category
with the lowest Akaike’s information criteria (AIC) value
for our reference models [29].
We developed the predictive models using multiple
logistic regression with backward elimination [27].
Beginning with the variable with the largest p-value, we
removed variables one at a time until ≤5 remained
(regardless of p-value). The five-variable limit was
selected to facilitate eventual implementation of risk
scores in resource-limited clinical settings [30, 31]. We
assessed the equality of the area under the receiver
operating characteristic curves (AUROC) between each
model (chi-squared test) [32]. AUROC measures the risk
score’s discriminatory power –where 1.0 indicates a
perfect test (i.e., 100 % sensitivity and 100 % specificity)
[33]. Likelihood ratio (LR) comparing successive models
were evaluated to confirm that variable removal did not
adversely affect the model’s predictive capacity. We also
compared LR-test statistics from each reduced model to
the full model.
We used the three predictive models to develop the
associated risk scores by assigning each variable in the
final models a predictor score equal to two times the
beta coefficient rounded to the nearest integer. We
doubled the coefficient to retain inherent discrimination
between betas, while keeping the absolute numbers
manageable. Patients with a high VL (≥1000 copies/ml)
and a risk score equal to or greater than a pre-specified
cutoff are classified as likely needing to switch to
second-line ART without a confirmatory VL test. For
each model, we assessed sensitivity, specificity, and
associated risk scores at cutoffs selected based on
clinically-acceptable model-performance criteria [34, 35].
Given the undesirable consequences of prematurely
switching persons to second-line therapy, we maintained
a high specificity threshold (>95.0 %) for all models to
minimize false positives. We also calculated the number
of patients in a hypothetical cohort of 10,000 ART
patients who would be switched without confirmatory
testing at each cutoff. We internally validated the model
and risk score performance using 1000 bootstrap
samples with replacement [27, 36]. Bootstrapping is a
process in which each iteration resamples a random
cohort of data points from within our full dataset and
assess validity of our calculated estimates using this “new”
sample. Bootstrapping is preferred over data splitting and
cross validation for internal validation [37–41]. Model
calibration was assessed using Hosmer-Lemeshow (HL)
goodness-of-fit tests (null hypothesis of statistically
significant difference between observed and predicted esti-
mates), and residuals were evaluated to verify appropriate
model fit [42].
Sensitivity analyses
We conducted a sensitivity analysis to evaluate model per-
formance using only study participants from resource-
limited settings. Given the implementation and policy
implications and hypothesized biological association of
ART duration and drug resistance, we tested multiple
forms of the treatment time variable (Additional file 1:
Table S1-S3). Models 4–6 evaluate therapy duration catego-
rized as <7, 7–24, and >24 months; models 7–9 dichoto-
mized duration (<7 vs ≥7 months). We compared these
alternatives to the primary models using AIC.
Results
Study population
Among 1045 participants, 305 had at least one VL ≥1000
copies/ml after week 16; 15 participants were excluded
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despite having two sequential VL ≥1000 copies/ml
because resistance results were unavailable at the time of
confirmed elevated VL, for a final sample of 290. Age
ranged from 19 to 65 years, and 53 % of persons
were male (Table 1). Mean CD4 at enrollment was
156 cells/mm3 and median VL at enrollment was
115,383 copies/ml.
Bivariable analyses
Among the 290 with at least one VL ≥1000 copies/ml,
53 % (148/290) resuppressed at the next visit. Among
the remaining 142 who did not resuppress, 75 had resist-
ance mutations (either transmitted or acquired) to NRTI
or NNRTI drugs. Thus, overall, NRTI or NNRTI resist-
ance was detected in 25.9 % (95 % CI 20.8 %, 30.9 %) of
participants with at least one VL ≥1000 copies/ml. Par-
ticipants with a higher VL at ART initiation (>100,000
copies/ml) (OR = 2.5, 95 % CI 1.4, 4.3) were more likely
to need ART change than participants with a lower VL
at ART initiation (Table 1). At time of VL elevation,
VL >100,000 copies/ml (OR = 3.3, 95 % CI 1.6, 6.9) or
10,000–100,000 copies/ml (OR = 5.7, 95 % CI 3.0,
10.7) also were associated with increased likelihood of
needing ART change, compared to participants with
VL <10,000 copies/ml. Participants who were on ther-
apy <7 months (OR = 5.1, 95 % CI 2.6, 9.8), or 7–12
months (OR = 3.2, 95 % CI 1.5, 6.8) were more likely
to need ART change than participants on therapy
>12 months. Participants whose BMI > 25.0 kg/m2 at
ART initiation were more likely to need ART change
at time of first VL ≥1000 copies/ml than participants
with BMI ≤25.0 kg/m2 (OR = 2.5, 95 % CI 1.4, 4.5).
Multivariable analyses
Model 1 - Including treatment initiation VL and CD4
The full model included ten predictor variables
(AUROC = 0.842) and showed acceptable HL test, failing
to reject the null hypothesis (p = 0.70). Our final model
contained five predictor variables: age <30, BMI > 25.0,
treatment initiation VL ≤100,000 copies/ml, time on
treatment, and VL at time of first VL ≥1000 (Table 2).
The AUROC was 0.8165 for the reduced model, which
showed acceptable calibration, (HL p = 0.12)
Model 2 - Excluding treatment initiation VL
The full model included nine predictor variables
(AUROC = 0.819) and showed acceptable calibration
(HL failed to reject null, p = 0.84). The reduced model
contained six predictor variables (AUROC = 0.807). To
meet the predefined criterion of a five-variable model,
we eliminated the variable with the lowest OR (self-re-
ported adherence). Our final model contained: age <30,
screening CD4 < 100 cells/mm3, BMI >25.0, time on
treatment, and VL at time of first VL ≥1000 (AUROC =
0.7981) (Table 2). The reduced model showed acceptable
calibration (HL p = 0.84).
Model 3 - Excluding treatment initiation VL and CD4
The full model included eight predictor variables
(AUROC = 0.801) and showed acceptable calibration
(HL p = 0.37). The final model contained: age <30, self-
reported missed medications, BMI > 25.0, time on
treatment, and VL at time of first VL ≥1000 (AUROC =
0.7937) (Table 2). The reduced model showed acceptable
calibration (HL, p = 0.10).
Reduced Model 1 performed slightly better than
reduced Model 2, but the difference was not significant
(p = 0.23). Reduced Model 3 performed slightly worse
again, but compared to reduced Model 1, the difference
was not statistically significant (p = 0.22) (Fig. 2). Boot-
strapping demonstrated consistent performance for all
models over 1000 replications. Further model diagnostics
demonstrated normally distributed residuals; graphs of
predicted probabilities against residuals suggested random
distribution.
Risk scores
The weighted risk scores ranged from 0–12 for Models
1 and 2, and 0–11 for Model 3 (Table 2). The maximum
attained score by any individual in the tested population
was 11 for each model. The predictive power of the
model was retained when predicted probabilities were
transformed to risk scores (AUROC for Model 1 = 0.813
(p = 0.69), Model 2 = 0.797 (p = 0.91), and Model 3 =
0.802 (p = 0.57)). A risk score cutoff of ≥9 met prede-
fined specificity threshold (>95.0 %) (Table 3).
We estimated the number of patients who would be
immediately switched to second-line therapy in a hypo-
thetical population of 10,000 ART patients receiving VL
monitoring. Given the proportion of patients who did
not resuppress and who harbored drug resistance
(~25 % of entire study population), Model 1 risk score
would accurately identify 700 persons who needed ART
change (true positives) and incorrectly classify 248 per-
sons as needing ART change when they did not (false
positives) (Fig. 3). At this same drug resistance preva-
lence, Model 2 would correctly switch 400 persons in
need of ART change and have 105 false positives. Model
3 would correctly switch 368 persons in need of ART
change, with 143 false positives. However, as the under-
lying drug resistance prevalence increases, so too does
the number of true positives as well as the ratio of
true positive:false positive. For example, with a preva-
lence of 55 % in a population of 10,000 ART patients
with a VL ≥1000 copies/ml, Model 1 would correctly
identify 1540 patients as needing ART change with
only 149 false positives.
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Table 1 Bivariable association of need for ART change and potential predictor characteristics
Predictor Overall
(n = 290) N (%)
Resistant
(n = 75)a N (%)
Not resistant or
resuppressed
(n = 215) N (%)
Unadjusted prevalence
OR (95 % CI)
p-value
Age, years 0.09
≤ 30 82 (28.3) 27 (36.0) 55 (25.6) 1.64 (0.93–2.87)
> 30 208 (71.7) 48 (64.0) 160 (74.4) 1.0
Sex 0.3
Male 154 (53.1) 36 (48.0) 118 (54.9) 0.76 (0.45, 1.28)
Female 136 (46.9) 39 (28.7) 97 (71.3) 1.0
BMI, kg/m2 0.002
Normal/low (<24.9) 229 (79.0) 50 (21.8) 179 (78.2) 1.0
High (>25.0) 31 (21.0) 25 (41.0) 36 (59.0) 2.48 (1.37–4.52)
CD4 at screening, cells/mm3 0.12
≤ 100 84 (71.0) 27 (36.0) 57 (26.5) 1.56 (0.89, 2.73)
> 100 206 (29.0) 48 (23.3) 158 (76.7) 1.0
Treatment initiation VL, copies/ml 0.001
≤ 100,000 135 (46.6) 23 (17.0) 112 (83.0) 1.0
> 100,000 155 (53.4) 52 (33.5) 103 (66.5) 2.46 (1.41, 4.30)
AIDS history 0.55
Yes 26 (9.0) 8 (30.8) 18 (69.2) 1.31 (0.54–3.14)
No 264 (91.0) 67 (25.4) 197 (74.6) 1.0
History of ART exposure 0.02
Yes 4 (1.4) 3 (75.0) 1 (25.0) 8.92 (0.91–87.1)
No 286 (98.6) 72 (25.2) 214 (74.8) 1.0
History of TB 0.14
Yes 60 (20.7) 11 (18.3) 49 (81.7) 1.0
No 230 (79.3) 64 (27.8) 166 (72.2) 1.72 (0.84–3.51)
Reported symptoms 0.22
Yes 37 (71.2) 11 (29.7) 26 (70.3) 2.75 (0.53–14.3)
No 15 (28.9) 2 (13.3) 13 (86.7) 1.0
Imperfect adherence 0.11
Yes 67 (25.6) 22 (32.8) 45 (67.2) 1.63 (0.89, 3.00)
No 195 (74.4) 45 (23.1) 150 (76.9) 1.0
Pill count, % taken 0.29
< 80 % 11 (22.4) 6 (54.5) 5 (45.5) 2.06 (0.53, 8.00)
≥ 80 % 38 (77.6) 14 (36.8) 24 (63.2) 1.0
Regimen frequency 0.84
Once daily (FTC/TDF/EFV QHS) 144 (49.7) 38 (26.4) 106 (73.6) 1.06 (0.62, 1.79)
Twice daily (3TC/ZDV BID + EFV QHS) 146 (50.3) 37 (25.3) 109 (74.7) 1.0
Time on therapy, monthsb <0.001
< 7 102 (35.2) 42 (41.2) 60 (58.8) 5.1 (2.6–9.8)
7–12 56 (19.3) 17 (30.4) 39 (69.6) 3.2 (1.5–6.8)
> 12 132 (45.5) 16 (12.1) 116 (87.9) 1.0
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Sensitivity analyses
Model performance was comparable when the study popu-
lation was restricted to persons from resource-limited
settings: AUROC =0.823 (Model 1), 0.812 (Model 2), and
0.804 (Model 3). Using the same risk score cutoff as in the
unrestricted model (≥9), the sensitivity for the three models
ranged from 10.0–26.0 %; specificity ranged from 97.4–
99.5 % (Table 3).
Discussion
Current WHO guidelines recommend confirmatory test-
ing for ART patients with high VL (≥1000 copies/ml). A
subset of patients will be resistant at the time of initial
elevated VL; for these persons, requiring confirmatory
testing unnecessarily delays switch to second-line ther-
apy. We developed a risk score using only parameters
that are likely to be available to providers in resource-
limited settings that successfully identifies person with
persistently elevated VL or are resistant and need imme-
diate ART change. The risk score performed well, >98 %
specific in most model iterations. Although increased
specificity comes at the cost of the lower sensitivity
(~15–30 %), this is less concerning as these “misses” will
undergo confirmatory testing as is the standard-of-care
for virological failure [1]. Rapidly switching patients with
resistance to more efficacious second-line therapy could
reduce transmission of resistant viral strains and transmis-
sion overall, and could prevent further declines in CD4
cell counts, resulting in meaningful public health benefits.
Utilizing this risk score may also reduce costs by
avoiding unnecessary confirmatory VL tests. Alternative
cost-saving strategies for virological monitoring include
pooling specimens and targeting VL tests based on
clinical or immunological criteria [1, 43–47]. Despite
potential cost-savings, pooling requires additional
laboratory support for linkage and deconstruction of
positive pools. Applying a conservative estimate of
treatment failure (16.0 % at 12 months) would trans-
late to >1,000,000 ART patients having an elevated
VL in sub-Saharan Africa alone [20]. Even a modest re-
duction in confirmatory test volume resulting from imple-
mentation of our algorithm could substantially reduce
expenditures and patients’ clinical deterioration.
Our risk score balances predictive ability and practicality.
Notably, given our goal of point-of-care application, we
considered only predictors that were likely available in
ART clinics within resource-limited settings. We also
sacrificed some precision for ease-of-use by collapsing
continuous variables into discrete categories and limiting
the number of included variables.
Maximizing specificity was essential to decrease
false positives. We selected 95.0 % as the lower
threshold for specificity, though selected risk score
thresholds had higher specificities (96.7–98.6 %). Even
at specificities >98 %, prematurely switching a patient
to second-line therapy (false positive) still occurs and
has significant person- and system-wide consequences.
For patients, false positive misclassification results in
lost potential life years from remaining on first-line
therapy. These are patients who, with improved ad-
herence, may resuppress. For the healthcare system,
premature second-line switching results in increased
drug costs– as much as 6–10 times the cost of first-
line therapy [26, 48]. Conversely, missing patients
who are resistant is also associated with substantial health
consequences and healthcare system costs, including
accumulation and potential transmission of resistant viral
strains. The current study used the WHO-accepted
threshold of <1000 copies/ml for defining resuppression,
and assumed that persons who resuppressed were not har-
boring clinically significant resistance mutations. However,
resistance may still be present at low-level viremia (<1000
Table 1 Bivariable association of need for ART change and potential predictor characteristics (Continued)
VLc, copies/ml <0.001
≤ 10,000 175 (60.4) 25 (14.3) 150 (85.7) 1.0
10,001–100,000 70 (24.1) 34 (48.6) 36 (51.4) 5.7 (3.0–10.7)
> 100,000 45 (15.5) 16 (35.6) 29 (64.4) 3.3 (1.6–6.9)
CD4 at failure, cells/mm3 0.18
≤ 200 77 (27.6) 24 (31.2) 53 (68.8) 1.49 (0.83–2.7)
> 200 202 (72.4) 47 (23.3) 155 (76.7) 1.0
Any change in therapy during study 0.28
Yes 42 (14.5) 8 (19.1) 34 (80.1) 0.64 (0.38–1.4)
No 248 (85.5) 67 (27.0) 181 (73.0) 1.0
aResistance indicates identified NRTI or NNRTI resistance mutations detected on stored specimens at time of first elevated (>1000 copies/ml) viral load
bTherapy duration defined by days, <7 months is <213; 7–12 months is 212–395, >12 months is >395 days
cViral load at time of first VL ≥1000 copies/ml
3TC lamivudine, ART antiretroviral therapy, BID twice daily, BMI body-mass index, CI confidence interval, EFV efavirenz, FTC emtricitabine, NNRTI non-nucleoside reverse
transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, OR odds ratio, QHS nightly, TB tuberculosis, TDF tenofovir, VL viral load, ZDV zidovudine
Rutstein et al. BMC Infectious Diseases  (2016) 16:280 Page 7 of 13
Table 2 Adjusted odds ratios and risk scores of need for ART change
Predictor Model 1 (with baseline VL) (n = 290), AUROC = 0.8165 Model 2 (without baseline VL) (n = 290), AUROC = 0.7981 Model 3 (without baseline VL or CD4) (n = 260), AUROC = 0.7937
Full model
OR (95 % CI)
Reduced
OR (95 % CI)
βb Predictor
scorea
Full model
OR (95 % CI)
Reduced model
OR (95 % CI)
βc Predictor
scorea
Full model
OR (95 % CI)
OR (95 % CI) βd Predictor
scorea
Age, years
≤ 30 2.2 (1.0–4.6) 2.1 (1.0–4.1) 0.72 1 1.8 (0.9–3.7) 1.8 (0.9–3.5) 0.59 1 1.6 (0.8–3.2) 1.7 (0.9–3.4) 0.53 1
> 30 1.0 1.0 0 1.0 1.0 0 1.0 1.0 0
Sex
Male 0.7 (0.4–1.4) - - - - 0.7 (0.3–1.3) - - - - 0.7 (0.4–1.4) - - - -
Female 1.0 - - - - 1.0 - - - - 1.0 - - - -
BMI, kg/m2
Normal/low (<24.9)
1.0 1.0 0 1.0 1.0 0 1.0 1.0 0
High (>25.0) 2.8 (1.2–6.4) 3.7 (1.8–7.8) 1.31 2 2.5 (1.1–5.6) 3.2 (1.6–6.6) 1.18 2 2.3 (1.1–4.1) 2.7 (1.2–5.7) 0.98 2
Treatment initiation
VL, copies/ml
≤ 100,000 1.0 1.0 0 - - - - - - - - - - - -
> 100,000 3.2 (1.5–7.1) 3.6 (1.8–7.0) 1.27 2 - - - - - - - - - - - -
Time on therapy,
months
< 7 4.2 (1.9–9.2) 4.2 (2.0–8.6) 1.43 3 3.9 (1.8–8.3) 4.3 (2.1–8.7) 1.45 3 3.6 (1.7–7.6) 3.7 (1.8–7.8) 1.32 3
7–12 2.0 (0.8–5.1) 2.9 (1.2–6.9) 1.07 2 1.9 (0.8–4.8) 3.1 (1.3–7.2) 1.13 2 1.9 (0.8–4.8) 2.1 (0.9–5.2) 0.76 2
> 12 1.0 1.0 0 1.0 1.0 0 1.0 0
VLe, copies/ml
≤ 10,000 1.0 1.0 0 1.0 1.0 0 1.0 1.0 0
10,001–100,000 7.3 (3.4–15.9) 6.3 (3.1–13.0) 1.85 4 7.4 (3.4–15.8) 6.3 (3.1–12.8) 1.85 4 6.5 (3.1–13.5) 6.5 (3.1–13.3) 1.87 4
> 100,000 2.8 (1.1–7.2) 2.7 (1.2–6.1) 0.99 2 2.7 (1.1–6.8) 3.1 (1.4–7.0) 1.15 2 2.7 (1.1–6.6) 3.0 (1.2–7.2) 1.10 2
CD4 at screening,
cells/mm3
≤ 100 1.8 (0.9–3.9) - - - - 2.6 (1.3–5.3) 2.2 (1.2–4.3) 0.81 2 - - - - - -
> 100 1.0 - - - - 1.0 1.0 0 - - - - - -
History of TB
Yes 1.0 - - - - 1.0 - - - - 1.0 - - - -
No 1.8 (0.7–4.5) - - - - 1.3 (0.6–3.2) - - - - 1.3 (0.6–3.2) - - - -
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Table 2 Adjusted odds ratios and risk scores of need for ART change (Continued)
Treatment changed
while on study
Yes 0.4 (0.1–1.3) - - - - 0.4 (0.1–1.2) - - - - 0.4 (0.1–1.3) - - - -
No 1.0 - - - - 1.0 - - - - 1.0 - - - -
Ever missed meds
Yes 1.8 (0.9–3.7) - - - - 2.1 (1.0–4.1) - - - - 2.1 (1.0–4.1) 1.8 (1.0–3.6) 0.61 1
No 1.0 - - - - 1.0 - - - - 1.0 0
aweighted; bconstant = −3.94; cconstant = −3.42; dconstant = −3.11
eViral load at time of first VL ≥1000 copies/ml
CI confidence interval, β beta regression coefficient, BMI body mass index, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, OR odds ratio, AUROC area under receiver
operating characteristic curve, VL viral load
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copies/ml) [49–53], and may be associated with subse-
quent virological failure [54], suggesting that policies for
treatment change thresholds, and thus the proposed
algorithm, may misclassify the need for ART switch in the
presence of resistance at lower viral loads. Modeling the
consequences of delayed second-line initiation versus
premature switching may help elucidate the trade-offs
inherent to these thresholds. Importantly, trade-offs may
vary by population: for example, providers may be more
willing to “risk” false positive results in HIV-infected
pregnant women given that viral suppression at time of
delivery prevents vertical transmission. Acceptable true
positive:false positive ratios may also differ depending
on anticipated time-to-referral, as the patient and
public health benefits of immediate switching may be
greater in settings with extensive delays in second-
line initiation [18, 19].
These data came from a controlled clinical trial,
and enrolled participants may not be representative of
larger ART populations. Viral suppression was similar
to other cohorts with nearly 30 % of participants
having a VL ≥1000 copies/ml after ≥16 weeks on
ART [20]. Participants received frequent virological
monitoring (every 8 weeks) in the study, which is
unlikely in the intended settings for this risk score.
The risk score used >12 months as the referent
category, however, sensitivity analyses with alternative
categorization of therapy duration did not change
model performance (Additional file 1). Furthermore,
all patients included in this analysis were initiated on
efavirenz-based first-line regimens – resistance pat-
terns and predictors may not apply to non-efavirenz-
based regimens depending on different barriers to
resistance mutations. Importantly, participants were
recruited largely from resource-limited settings and
the risk score performed well in this subgroup.
Furthermore, PEARL’s broad inclusion criteria im-
proves generalizability. Study-driven CD4 cell count
eligibility were consistent with WHO guidelines (<300
cells/mm3), but these guidelines have since changed,
expanding ART eligibility to HIV-infected persons
earlier in the course of disease (<500 cells/mm3) [1].
If CD4 is included (Model 2), having more patients
with high CD4 at treatment initiation could mean
that fewer patients reach the switch score threshold,
potentially dampening the efficiency gains of the
algorithm.
Fig. 2 Receiver operating characteristic (ROC) curves for Models 1–3.
The area under an ROC curve is a measure of model performance.
Specifically, the area measures discrimination – in this case the ability of
the predictive model to correctly classify persons with and without
resistance. Model 1, in which we assumed that viral load and CD4 cell
counts from time of treatment initiation were available, performed the
best, and had an area under the ROC curve of 0.8165. In Model 2, when
viral load from treatment initiation was excluded as an eligible predictor,
performed slightly less well (area under ROC curve of 0.7981). Finally, in
Model 3, we assumed that neither viral load nor CD4 cell counts from
time of treatment initiation were available. This model performed the
poorest of all three models evaluated, with an area under the ROC
curve of 0.794 – although this difference was not statistically significant
and may not be clinically meaningful
Table 3 Performance of models and derived risk scores
Predictor Model with baseline VL (n = 290) Model without baseline VL (n = 290) Model without baseline VL or CD4 (n = 260)
Cutoff Sensitivity Specificity Cutoff Sensitivity Specificity Cutoff Sensitivity Specificity
Unrestricted (RLS & non-RLS)
Modela 0.657 22.7 % 98.1 % 0.640 22.7 % 97.2 % 0.741 13.4 % 98.4 %
Weighted risk score ≥9 28.0 % 96.7 % ≥9 16.0 % 98.6 % ≥9 14.7 % 98.1 %
Restricted (RLS only)
Modela 0.653 28.0 % 97.2 % 0.697 18.7 % 98.1 % 0.691 14.9 % 98.4 %
Weighted risk score ≥9 26.0 % 97.4 % ≥9 10.0 % 99.5 % ≥9 14.0 % 99.5 %
aCutoff values for the models are thresholds derived by summing the beta coefficients and converting to a probability RLS, resource-limited setting; VL, viral load
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Among patients with ≥1 elevated VL, resistance
rates were lower than observed in sub-Saharan
African cohorts (as high as 70 %) [2, 11, 55–57],
however, this may result from more frequent VL
monitoring in the study, which increases the likeli-
hood of detecting transiently elevated VL. A higher
prevalence of resistance would favor use of the risk
score, increasing the score’s positive predictive value.
Assuming 55 % resistance among patients with an
elevated VL, we demonstrated that in a hypothetical
cohort of 10,000 ART patients, >1500 would be ap-
propriately classified as resistant and switched imme-
diately, with only 150 false positives.
Conclusions
To our knowledge, this risk score is the first to
identify the need for immediate ART change among
persons with a single elevated VL. We successfully
identified predictors that reliably distinguished be-
tween persons who do and do not need immediate
ART change from first-line regimens. Our risk score
is sensitive to realities in resource-limited settings: we
used a limited number of readily-available categorical
variables and minimized false positive results. This
model is a promising opportunity to quickly transition
patients with probable resistance to more effective
regimens – improving ART morbidity and mortality
outcomes. Using this risk score may reduce transmission
of resistant viral strains and save healthcare systems scarce
resources by reducing personnel and equipment costs in-
curred with unnecessary confirmatory VL testing.
These potential benefits should be assessed and exter-
nally validated prospectively by evaluating the effect
of the risk score on health outcomes and resource
utilization, taking into account the trade-offs associ-
ated with misclassifying even a small subset of pa-
tients as needing ART change when they do not [31].
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